I was lucky to catch PH on the phone about 3 weeks ago discussing the CHM and IMU pipelines. While all of them have the potential to become a huge success I was more interested in the NK-cell platform and CDH 17 due to their versatility.
Here the answers to my 2 burning questions that I found very important:
1. Yes, the NK's are one of the hottest in the field of oncology research.
2.Yes, if IMU's CF 33 turns a "cold cancer" into a "hot" one by opening up a solid tumour to make CAR-T CD 19 useful for solid tumours then there is no chemical or biological hurdle that it can't be used for a CDH 17 based CAR-T as well. Of course, firstly the CF 33 trials must be successful and secondly CD 17 in general must be validated by the FDA / TGA ..... But if both happens then the value of CDH 17 should increase significantly CHM's value / MC.
GLTA
CHM Price at posting:
11.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)